New drug can successfully treat patients typically resistant to high blood pressure treatment

Written By :  Dr Rashi Prakash
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-11-10 04:15 GMT   |   Update On 2022-11-10 04:15 GMT

High blood pressure is the main cause of strokes, and a common cause of heart attacks and kidney failure. In most people with the condition, the cause is unknown, and they need life-long treatment through drugs w ho eventually become resistant to it. A new drug called Baxdrostat has been shown to significantly reduce high blood pressure (hypertension) in patients who may not respond...

Login or Register to read the full article

High blood pressure is the main cause of strokes, and a common cause of heart attacks and kidney failure. In most people with the condition, the cause is unknown, and they need life-long treatment through drugs w ho eventually become resistant to it.

A new drug called Baxdrostat has been shown to significantly reduce high blood pressure (hypertension) in patients who may not respond to current treatments for the condition, according to results from a phase II trial, published in the New England Journal of Medicine and presented at the American Heart Association Scientific Sessions conference, the trial results represent the first time that this long-sought new class of drugs to treat resistant hypertension has been developed and successfully tested.

The trial, conducted over 12 weeks, gave 248 patients either a once daily dose of Baxdrostat at varying amounts or a placebo. At entry to the trial, none of these patients' blood pressure was controlled despite taking 3 or more medicines for high blood pressure. The doses of Baxdrostat, taken in addition to patients' usual medicines, varied from 2mg, to 1mg, to 0.5mg. At the end of the 12 weeks, the group who received the highest amount of Baxdrostat saw a 20-point fall in blood pressure. There was an 11-point difference between this group and that which received the placebo treatment, a difference rarely seen in any single drug to reduce blood pressure.

The results of this first-of-its-kind drug are exciting, although more testing is required before we can draw comparisons with any existing medications. But Baxdrostat could potentially offer hope to many people who do not respond to traditional hypertension treatment.

The researchers concluded that this study shows the drug causes a marked fall in blood pressure in patients whose hypertension is resistant to usual drugs, and that this type of hypertension is partly due to excess production of the aldosterone hormone.

Reference:

New drug can successfully treat patients typically resistant to high blood pressure treatment; New England Journal of Medicine.

Tags:    
Article Source : New England Journal of Medicine

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News